Real-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study

Basit Öğe Kaydı
dc.authoridDulgar, Ozgecan/0000-0002-0678-4024
dc.contributor.authorDulgar, Ozgecan
dc.contributor.authorTurker, Sema
dc.contributor.authorBasaran, Gul
dc.contributor.authorAraz, Murat
dc.contributor.authorSumbul, Ahmet Taner
dc.contributor.authorCaglayan, Dilek
dc.contributor.authorGumusay, Ozge
dc.date.accessioned2024-10-29T17:58:36Z
dc.date.available2024-10-29T17:58:36Z
dc.date.issued2024
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractWe aimed to evaluate the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab plus trastuzumab and taxane. We reviewed the medical records of patients who were diagnosed with Human Epidermal Growth Factor Receptor 2 (HER-2) positive metastatic breast cancer and received pertuzumab and then TDM-1 between January 2014 and January 2021 from twenty- five cancer centers. The Kaplan- Meier method estimated progression-free survival (PFS) and overall survival (OS). Additionally, objective response rate (ORR), clinical benefit rate (CBR), and safety were evaluated. One hundred fifty-three patients were included,79.1% of the patients received TDM-1 in the second line, 90.8% had visceral metastasis, and 30.7% had central nervous system involvement. The PFS and OS of TDM-1 were evaluated according to the number of previous lines (on the 2nd line or more than two lines) metastatic sites (visceral and non-visceral) and the presence of central nervous metastasis. In TDM-1 therapy, PFS in second line therapy was ten months (95% CI: 7.7 - 12.2); this was statistically higher than later-line PFS, which was six months (95% CI: 3.3 to 8.6) (p = 0.004). The median OS time was 25 months (95% CI: 21.0 to 28.9) in patients treated with TDM-1 in the second line and 19 months (95% CI: 12.3 to 25.6) in patients who received later than the second line(p = 0.175). There were no significant differences in PFS time of patients with and without visceral and central nervous metastases. Our study showed that TDM-1 was also effective in patients using pertuzumab, contributes significantly to PFS when used in the second line compared to its use in the later line, and does not make any difference in OS.
dc.identifier.doi10.1080/1120009X.2024.2366683
dc.identifier.issn1120-009X
dc.identifier.issn1973-9478
dc.identifier.pmid38904164
dc.identifier.scopus2-s2.0-85196637419
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1080/1120009X.2024.2366683
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14409
dc.identifier.wosWOS:001251618800001
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTaylor & Francis Ltd
dc.relation.ispartofJournal of Chemotherapy
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectHER2 positive breast cancer
dc.subjectTrastuzumab emtansine
dc.subjectPertuzumab
dc.subjectAntibody-drug conjugates
dc.titleReal-world data on the efficacy and safety of trastuzumab emtansine in patients with metastatic breast cancer previously treated with pertuzumab: Turkish oncology group multicenter study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu